Who are CLDM 1% gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tedizolid IV, QS azithromycin tablets, Topical Clindamycin, Azithromycin 3 days, Azithromycin and amoxicillin, Clindamycin Topical Gel 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cldm-1-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CLDM 1% gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CLDM 1% gel (CLDM 1% gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Dermatology.

marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

CLDM 1% gel (CLDM 1% gel) — GlaxoSmithKline. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CLDM 1% gel TARGET	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Tedizolid IV	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
QS azithromycin tablets	QS azithromycin tablets	University of Taubate	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Topical Clindamycin	Topical Clindamycin	University of Toronto	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

GlaxoSmithKline · 2 drugs in this class
Balmoral Medical company · 1 drug in this class
Generic (originally Upjohn/Pfizer) · 1 drug in this class
Hospital General Universitario Elche · 1 drug in this class
Janssen-Cilag, S.A. · 1 drug in this class
Jinnah Postgraduate Medical Centre · 1 drug in this class
Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
Actavis Inc. · 1 drug in this class
University of Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CLDM 1% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/cldm-1-gel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing